238 related articles for article (PubMed ID: 26364215)
1. An evaluation of indirubin analogues as phosphorylase kinase inhibitors.
Begum J; Skamnaki VT; Moffatt C; Bischler N; Sarrou J; Skaltsounis AL; Leonidas DD; Oikonomakos NG; Hayes JM
J Mol Graph Model; 2015 Sep; 61():231-42. PubMed ID: 26364215
[TBL] [Abstract][Full Text] [Related]
2. Docking and ADMET prediction of few GSK-3 inhibitors divulges 6-bromoindirubin-3-oxime as a potential inhibitor.
Nisha CM; Kumar A; Vimal A; Bai BM; Pal D; Kumar A
J Mol Graph Model; 2016 Apr; 65():100-7. PubMed ID: 26967552
[TBL] [Abstract][Full Text] [Related]
3. Kinetics, in silico docking, molecular dynamics, and MM-GBSA binding studies on prototype indirubins, KT5720, and staurosporine as phosphorylase kinase ATP-binding site inhibitors: the role of water molecules examined.
Hayes JM; Skamnaki VT; Archontis G; Lamprakis C; Sarrou J; Bischler N; Skaltsounis AL; Zographos SE; Oikonomakos NG
Proteins; 2011 Mar; 79(3):703-19. PubMed ID: 21287607
[TBL] [Abstract][Full Text] [Related]
4. 7-Bromoindirubin-3'-oxime induces caspase-independent cell death.
Ribas J; Bettayeb K; Ferandin Y; Knockaert M; Garrofé-Ochoa X; Totzke F; Schächtele C; Mester J; Polychronopoulos P; Magiatis P; Skaltsounis AL; Boix J; Meijer L
Oncogene; 2006 Oct; 25(47):6304-18. PubMed ID: 16702956
[TBL] [Abstract][Full Text] [Related]
5. Structural basis for the synthesis of indirubins as potent and selective inhibitors of glycogen synthase kinase-3 and cyclin-dependent kinases.
Polychronopoulos P; Magiatis P; Skaltsounis AL; Myrianthopoulos V; Mikros E; Tarricone A; Musacchio A; Roe SM; Pearl L; Leost M; Greengard P; Meijer L
J Med Chem; 2004 Feb; 47(4):935-46. PubMed ID: 14761195
[TBL] [Abstract][Full Text] [Related]
6. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins.
Myrianthopoulos V; Magiatis P; Ferandin Y; Skaltsounis AL; Meijer L; Mikros E
J Med Chem; 2007 Aug; 50(17):4027-37. PubMed ID: 17665890
[TBL] [Abstract][Full Text] [Related]
7. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
Darshit BS; Balaji B; Rani P; Ramanathan M
J Mol Graph Model; 2014 Sep; 53():31-47. PubMed ID: 25064440
[TBL] [Abstract][Full Text] [Related]
8. An inhibitor-driven study for enhancing the selectivity of indirubin derivatives towards leishmanial Glycogen Synthase Kinase-3 over leishmanial cdc2-related protein kinase 3.
Efstathiou A; Gaboriaud-Kolar N; Smirlis D; Myrianthopoulos V; Vougogiannopoulou K; Alexandratos A; Kritsanida M; Mikros E; Soteriadou K; Skaltsounis AL
Parasit Vectors; 2014 May; 7():234. PubMed ID: 24886176
[TBL] [Abstract][Full Text] [Related]
9. Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2.
Czeleń P; Szefler B
J Mol Model; 2015 Apr; 21(4):74. PubMed ID: 25754137
[TBL] [Abstract][Full Text] [Related]
10. Binding and stability of indirubin-3-monoxime in the GSK3β enzyme: a molecular dynamics simulation and binding free energy study.
Saravanan K; Hunday G; Kumaradhas P
J Biomol Struct Dyn; 2020 Mar; 38(4):957-974. PubMed ID: 30963817
[TBL] [Abstract][Full Text] [Related]
11. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
Yan L; Lai F; Chen X; Xiao Z
Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
[TBL] [Abstract][Full Text] [Related]
12. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
13. Structural basis of valmerins as dual inhibitors of GSK3β/CDK5.
Li X; Wang X; Tian Z; Zhao H; Liang D; Li W; Qiu Y; Lu S
J Mol Model; 2014 Sep; 20(9):2407. PubMed ID: 25142337
[TBL] [Abstract][Full Text] [Related]
14. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6.
Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP
Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919
[TBL] [Abstract][Full Text] [Related]
15. Molecular dynamics simulation and free energy calculation studies of kinase inhibitors binding to active and inactive conformations of VEGFR-2.
Wu X; Wan S; Wang G; Jin H; Li Z; Tian Y; Zhu Z; Zhang J
J Mol Graph Model; 2015 Mar; 56():103-12. PubMed ID: 25594497
[TBL] [Abstract][Full Text] [Related]
16. Structural features contributing to complex formation between glycogen phosphorylase and phosphorylase kinase.
Xu YH; Carlson GM
Biochemistry; 1999 Jul; 38(30):9562-9. PubMed ID: 10423233
[TBL] [Abstract][Full Text] [Related]
17. Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.
Vougogiannopoulou K; Ferandin Y; Bettayeb K; Myrianthopoulos V; Lozach O; Fan Y; Johnson CH; Magiatis P; Skaltsounis AL; Mikros E; Meijer L
J Med Chem; 2008 Oct; 51(20):6421-31. PubMed ID: 18816110
[TBL] [Abstract][Full Text] [Related]
18. Structure and inhibitor specificity of the PCTAIRE-family kinase CDK16.
Dixon-Clarke SE; Shehata SN; Krojer T; Sharpe TD; von Delft F; Sakamoto K; Bullock AN
Biochem J; 2017 Feb; 474(5):699-713. PubMed ID: 28057719
[TBL] [Abstract][Full Text] [Related]
19. Feasibility of using molecular docking-based virtual screening for searching dual target kinase inhibitors.
Zhou S; Li Y; Hou T
J Chem Inf Model; 2013 Apr; 53(4):982-96. PubMed ID: 23506306
[TBL] [Abstract][Full Text] [Related]
20. 6-Br-5methylindirubin-3'oxime (5-Me-6-BIO) targeting the leishmanial glycogen synthase kinase-3 (GSK-3) short form affects cell-cycle progression and induces apoptosis-like death: exploitation of GSK-3 for treating leishmaniasis.
Xingi E; Smirlis D; Myrianthopoulos V; Magiatis P; Grant KM; Meijer L; Mikros E; Skaltsounis AL; Soteriadou K
Int J Parasitol; 2009 Oct; 39(12):1289-303. PubMed ID: 19445946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
